Hemogenyx Pharmaceuticals Plc's latest marketcap:
As of 06/28/2025, Hemogenyx Pharmaceuticals Plc's market capitalization has reached $10.75 M. According to our data, Hemogenyx Pharmaceuticals Plc is the 39863th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.
| Market Cap | 10.75 M |
| Revenue (ttm) | 0 |
| Net Income (ttm) | -7,034,792 |
| Shares Out | 0 |
| EPS (ttm) | -2.13 |
| Forward PE | 0.00 |
| Ex-Dividend Date | n/a |
| Earnings Date | 06/27/2025 |
Hemogenyx Pharmaceuticals Plc's yearly market capitalization.
| Date | Market Cap | Change (%) | Global Rank |
|---|---|---|---|
| 06/28/2025 | $10.75 M | -46.39% | 39863 |
| 12/31/2024 | $17.77 M | -48.41% | 46746 |
| 12/29/2023 | $34.44 M | 120.18% | 45088 |
| 12/30/2022 | $15.64 M | -37.12% | 43392 |
| 12/31/2021 | $24.87 M | -56.46% | 41437 |
| 12/31/2020 | $57.13 M | 512.38% | 38303 |
| 12/31/2019 | $9.33 M | -3.22% | 35702 |
| 12/31/2018 | $9.64 M | -19.87% | 34365 |
| 12/29/2017 | $12.03 M | 32900 |
Company Profile
About Hemogenyx Pharmaceuticals Plc
Hemogenyx Pharmaceuticals Plc is a clinical-stage biotechnology company dedicated to discovering, developing, and commercializing innovative therapies for blood cancer and other critical diseases.
Key Product Candidates
- HEMO-CAR-T Therapy: A lead product candidate targeting relapsed and/or refractory acute myeloid leukemia (AML), with potential for a cure.
- Chimeric Bait Receptor: Developed to treat COVID-19, brain cancers, and certain neurodegenerative diseases.
- CDX Bi-Specific Antibody: Designed to eliminate hematopoietic stem cells/progenitors using bi-specific antibodies.
- Cell Therapy Products: Focused on bone marrow and hematopoietic stem cell transplantation.
Company Background
Founded in 2013, Hemogenyx Pharmaceuticals Plc is headquartered in London, United Kingdom, and remains at the forefront of cutting-edge biotechnological advancements.
Frequently Asked Questions
-
What is Hemogenyx Pharmaceuticals Plc's (OTC-HOPHF) current market cap?As of 06/28/2025, Hemogenyx Pharmaceuticals Plc (including the parent company, if applicable) has an estimated market capitalization of $10.75 M USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
-
Where does Hemogenyx Pharmaceuticals Plc (OTC-HOPHF) rank globally by market cap?Hemogenyx Pharmaceuticals Plc global market capitalization ranking is approximately 39863 as of 06/28/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.